These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 38378730)
1. Comparative physicochemical and structural characterisation studies establish high biosimilarity between BGL-ASP and reference insulin aspart. Ghade NS; Thappa DK; Lona J; Krishnan AR; Sonar SM Sci Rep; 2024 Feb; 14(1):4224. PubMed ID: 38378730 [TBL] [Abstract][Full Text] [Related]
2. Comparative assessment of immunogenicity of recombinant insulin Aspart from BioGenomics and its originator NovoRapid® in adult patients with type 2 diabetes mellitus. Mishra A; Dongre S; Kulkarni G; Deshmane R; Thappa D; Ghade N; Lona J; Kokatam S; Deo A; Sonar S; Krishnan A J Endocrinol Invest; 2024 Jun; 47(6):1435-1446. PubMed ID: 38147290 [TBL] [Abstract][Full Text] [Related]
3. In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart. Mishra AG; Deshmane RB; Thappa DK; Lona J; Ghade NS; Sonar SM; Krishnan AR BioDrugs; 2023 Sep; 37(5):709-719. PubMed ID: 37285012 [TBL] [Abstract][Full Text] [Related]
4. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial. Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Miossec P; Mukherjee B; Shah VN Diabetes Technol Ther; 2020 Jul; 22(7):516-526. PubMed ID: 32068436 [No Abstract] [Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins. Chen W; Lu J; Plum-Mörschel L; Andersen G; Zijlstra E; He A; Xie T; Li L; Hao C; Gan Z; Heise T Diabetes Obes Metab; 2023 Dec; 25(12):3817-3825. PubMed ID: 37735841 [TBL] [Abstract][Full Text] [Related]
6. Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial. Thrasher J; Polsky S; Hovsepian L; Nowotny I; Pierre S; Bois De Fer B; Bhargava A; Mukherjee B; Garg SK Diabetes Technol Ther; 2020 Sep; 22(9):666-673. PubMed ID: 31833801 [No Abstract] [Full Text] [Related]
7. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Mukherjee B; Shah VN Diabetes Technol Ther; 2020 Feb; 22(2):85-95. PubMed ID: 31804851 [No Abstract] [Full Text] [Related]
8. 'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar. Gaylis N; Both C; Lemke L; von Richter O; Yamauchi P Adv Ther; 2024 May; 41(5):1795-1814. PubMed ID: 38514505 [TBL] [Abstract][Full Text] [Related]
9. Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes. Kapitza C; Nosek L; Schmider W; Teichert L; Nowotny I Diabetes Technol Ther; 2020 Apr; 22(4):278-284. PubMed ID: 31825248 [No Abstract] [Full Text] [Related]
10. Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial. Shah VN; Al-Karadsheh A; Barnes C; Mandry J; Nakhle S; Wernicke-Panten K; Kramer D; Schmider W; Pierre S; Teichert L; Rotthaeuser B; Mukherjee B; Bailey TS Diabetes Obes Metab; 2024 Feb; 26(2):540-547. PubMed ID: 37880868 [TBL] [Abstract][Full Text] [Related]
11. Biosimilars and Novel Insulins. Ampudia-Blasco FJ Am J Ther; 2020; 27(1):e52-e61. PubMed ID: 31764128 [TBL] [Abstract][Full Text] [Related]
16. Leveraging Clinical Pharmacology Data to Assess Biosimilarity and Interchangeability of Insulin Products. Vaidyanathan J; Wang YC; Tran D; Seo SK Clin Pharmacol Ther; 2023 Apr; 113(4):794-802. PubMed ID: 36052570 [TBL] [Abstract][Full Text] [Related]
17. Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. Haahr H; Heise T Clin Pharmacokinet; 2020 Feb; 59(2):155-172. PubMed ID: 31667789 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study. Hövelmann U; Raiter Y; Chullikana A; Liu M; Donnelly C; Lawrence T; Sengupta N; Cl G; Ranganna G; Barve A Diabetes Obes Metab; 2021 Dec; 23(12):2670-2678. PubMed ID: 34378861 [TBL] [Abstract][Full Text] [Related]
19. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira. McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743 [TBL] [Abstract][Full Text] [Related]